The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance

Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors

(2012) Fritz Lai et al.   MELANOMA RESEARCH

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

(2011) Inna V. Fedorenko et al.   BIOCHEMICAL PHARMACOLOGY

Mutant BRAF Melanomas—Dependence and Resistance

(2011) Poulikos I. Poulikakos et al.   CANCER CELL

Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options

(2011) J. Villanueva et al.   CANCER RESEARCH

Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737

(2011) K. M. Lucas et al.   CLINICAL CANCER RESEARCH

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Resistance to BRAF Inhibition in Melanomas

(2011) David B. Solit et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

BH3 mimetics activate multiple pro-autophagic pathways

(2011) S A Malik et al.   ONCOGENE

Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress

(2011) L Dong et al.   ONCOGENE

Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma

(2011) Karianne Risberg et al.   PLoS One

The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53

(2011) Steven N. Reuland et al.   PLoS One

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

(2011) S. R. Oakes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

(2010) K H T Paraiso et al.   BRITISH JOURNAL OF CANCER

MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720

(2010) C. C. Jiang et al.   CLINICAL CANCER RESEARCH

AMP kinase–mediated activation of the BH3-only protein Bim couples energy depletion to stress-induced apoptosis

(2010) Caoimhín G. Concannon et al.   JOURNAL OF CELL BIOLOGY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

(2010) John T. Lee et al.   Pigment Cell & Melanoma Research

BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs

(2010) E. M. Carrington et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS

(2010) C C Jiang et al.   Cell Death & Disease

Small molecules and targeted therapies in distant metastatic disease

(2009) P. Hersey et al.   ANNALS OF ONCOLOGY

Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation

(2009) Bin Zheng et al.   MOLECULAR CELL

RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway

(2009) Angela M. Keuling et al.   PLoS One

Melanocytes: From Morphology to Application

(2009) A. Santiago-Walker et al.   SKIN PHARMACOLOGY AND PHYSIOLOGY

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH

Up-regulation of Mcl-1 Is Critical for Survival of Human Melanoma Cells upon Endoplasmic Reticulum Stress

(2008) C. C. Jiang et al.   CANCER RESEARCH

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

(2008) N. K. Haass et al.   CLINICAL CANCER RESEARCH

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

(2008) A. R. Shoemaker et al.   CLINICAL CANCER RESEARCH

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

(2008) Mark S. Cragg et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY